To validate specificity:
Perform knockout controls: Use AtTim17-1 mutant lines (e.g., T-DNA insertions at −402 bp or +360 bp) and compare protein levels via immunoblotting. A 60–70% transcript reduction in mutants should correlate with diminished antibody signal .
Cross-reactivity tests: Validate using isoforms (e.g., AtTim17-2 or AtTim17-3). Antibodies targeting AtTim17-1 may cross-react with AtTim17-2 due to shared epitopes, but isoforms can be distinguished by molecular weight (32 kDa vs. 29 kDa) .
Recombinant protein validation: Express recombinant Tim17-1 and Tim17-2 to confirm antibody binding specificity .
Western blot: Use 10–20 µg mitochondrial lysate, 12% SDS-PAGE, and antibodies like ab192246 (predicted 18 kDa, observed 17 kDa) .
Immunofluorescence: Fix cells with 4% paraformaldehyde, permeabilize with 0.1% Triton X-100, and use secondary antibodies (e.g., Alexa Fluor® 555) for mitochondrial co-localization .
Immunoprecipitation: Employ digitonin-solubilized mitochondria and Ni-agarose beads for Tim17-1 complex isolation .
Yeast suppression assays: Overexpress TIM17 in ilv5Δ or abf2Δ mutants to assess mtDNA retention (76% suppression in ilv5Δ; 32% in abf2Δ) .
Human cybrid models: Introduce TIM17A into NT2 cells with A3243G mutant mtDNA. Overexpression stabilizes mtDNA levels (13–17-fold increase vs. empty vector) .
QRT-PCR validation: Monitor mtDNA copy number using ND1 (mtDNA) vs. 18S rRNA (nuclear DNA) primers .
Epitope mapping: Use truncated Tim17-1/2 constructs to identify antibody-binding regions .
Competition assays: Pre-incubate antibodies with recombinant Tim17-2 to block non-specific binding .
Subcellular fractionation: Isolate mitochondria rigorously to reduce cytosolic contamination .
Transmembrane domains (TMs): TM1 and TM4 are essential for proper localization (Fig. 1A). Deletion of TM1 (ΔN50) or TM4 (ΔC31) disrupts mitochondrial integration .
C-terminal ITS: Residues 121–152 in T. brucei Tim17 contain an internal targeting signal (ITS) sufficient for GFP import .
Crosslinking with preproteins: Use cysteine-rich Tim17-1 mutants and bifunctional crosslinkers (e.g., BMH) to trap transient interactions .
Electrophysiology: Incorporate Tim17-1 into proteoliposomes to measure channel activity in response to presequence peptides .
Charge-swap mutagenesis: Replace conserved negative charges (e.g., Glu94) to disrupt presequence binding .